CytoMed Therapeutics (GDTC) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Vyome (HIND) over the past year, losing 59.8% versus a loss of 75.9%. CytoMed Therapeutics is the larger company by market cap ($9.0 million vs $8.4 million), about 1.1 times the size. CytoMed Therapeutics converts more of its revenue into profit, with a net margin of -1227.1% versus -3209.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | HIND |
|---|---|---|
| Share price | $0.755 | $1.20 |
| Market cap | $9.01M | $8.42M |
| 1-day change | -2.33% | -17.24% |
| YTD return | -43.45% | -65.12% |
| 1-year return | -59.84% | -75.90% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 0.25 |
| EPS (TTM) | $-0.23 | $4.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $252.26K | $319.71K |
| Revenue growth (YoY) | +395.88% | +24.43% |
| Net income (latest FY) | $-3.10M | $-10.26M |
| Gross margin | — | 68.43% |
| Operating margin | — | -3269.35% |
| Net margin | -1227.07% | -3209.75% |
| 52-week high | $2.12 | $5.88 |
| 52-week low | $0.68 | $1.20 |
| Distance from 52-week high | -64.39% | -79.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +450.99% | +635.83% |
| Average volume | 15.69K | 13.92K |
| Shares outstanding | 11.93M | 7.02M |
| Employees | 42 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDTC has outperformed HIND by 16.1 percentage points over the past year.
- CytoMed Therapeutics is more profitable, keeping -1227.1 cents of every revenue dollar as net income versus -3209.7 cents for Vyome.
- CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +24.43%).
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
GDTC vs HIND FAQ
Which is bigger, CytoMed Therapeutics or Vyome?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $9.01M compared with $8.42M for Vyome (HIND).
Which stock has performed better over the past year, GDTC or HIND?
GDTC returned -59.84% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.